Successful Pre- and Posttransplant Sofosbuvir-Based Anti-Hepatitis C Virus Treatment in Persons Living With Human Immunodeficiency Virus Infection | Zendy

Giovanni Guaraldi | Zendy; Roberto Rossotti | Zendy; Gabriella Verucchi | Zendy; Marcello Tavio | Zendy; L. Pasulo | Zendy; Barbara Beghetto | Zendy; Giovanni Dolci | Zendy; Giulia Nardini | Zendy; Lorenzo Badia | Zendy; Anna Magliano | Zendy; Maria Cristina Moioli | Zendy; Massimo Puoti | Zendy; Giovanna Travi | Zendy; Annamaria Pazzi | Zendy; Luciano De Carlis | Zendy; Alessandro Giacomoni | Zendy; Andrea Lauterio | Zendy; I. Mangoni | Zendy; Stefano Di Sandro | Zendy; Fabio Ferla | Zendy; S. Fagiuoli | Zendy; M. Colledan | Zendy; Giuliana Cologni | Zendy; Fabrizio Di Benedetto | Zendy; Giuseppe Tarantino | Zendy; Valentina Serra | Zendy

Open Access

Successful Pre- and Posttransplant Sofosbuvir-Based Anti-Hepatitis C Virus Treatment in Persons Living With Human Immunodeficiency Virus Infection

Author(s) -

Giovanni Guaraldi,

Roberto Rossotti,

Gabriella Verucchi,

Marcello Tavio,

L. Pasulo,

Barbara Beghetto,

Giovanni Dolci,

Giulia Nardini,

Lorenzo Badia,

Anna Magliano,

Maria Cristina Moioli,

Massimo Puoti,

Giovanna Travi,

Annamaria Pazzi,

Luciano De Carlis,

Alessandro Giacomoni,

Andrea Lauterio,

I. Mangoni,

Stefano Di Sandro,

Fabio Ferla,

S. Fagiuoli,

M. Colledan,

Giuliana Cologni,

Fabrizio Di Benedetto,

Giuseppe Tarantino,

Valentina Serra

Publication year - 2017

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofx065

Subject(s) - medicine , sofosbuvir , hepatitis c virus , virology , liver transplantation , human immunodeficiency virus (hiv) , virus , transplantation , immunology , ribavirin

This retrospective study reports the data of sofosbuvir-based anti-hepatitis C virus treatment in 24 candidates and 24 recipients of liver transplantation coinfected with human immunodeficiency virus. Sustained virologic response was cumulatively 85% (90% and 100% in those treated with optimal schedules pre- and posttransplant, respectively)

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research